Improved pulmonary function and exercise tolerance despite persistent pulmonary fibrosis over 1 year after severe COVID-19 infection.

Autor:	McGroder CF; Medicine/Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, USA., Salvatore MM; Radiology, Columbia University Medical Center, New York, New York, USA., D'Souza BM; Radiology, Columbia University Medical Center, New York, New York, USA., Hoffman EA; Radiology/Medicine/Biomedical Engineering, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA., Baldwin MR; Medicine/Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, USA., Garcia CK; Medicine/Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, USA ckg2116@cumc.columbia.edu.; Precision Medicine Initiative and the Center for Precision Medicine and Genomics, Columbia University, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Thorax [Thorax] 2024 Apr 15; Vol. 79 (5), pp. 472-475. Date of Electronic Publication: 2024 Apr 15.
DOI:	10.1136/thorax-2023-220370
Abstrakt:	We conducted a prospective single-centre cohort study of 104 multi-ethnic severe COVID-19 survivors from the first wave of the pandemic 15 months after hospitalisation. Of those who were assessed at 4 and 15 months, improvement of ground glass opacities correlated with worsened fibrotic reticulations. Despite a high prevalence of fibrotic patterns (64%), pulmonary function, grip strength, 6 min walk distance and frailty normalised. Overall, dyspnoea, cough and exhaustion did not improve and were not correlated with pulmonary function or radiographic fibrosis at 15 months, suggesting non-respiratory aetiologies. Monitoring persistent, and often subclinical, fibrotic interstitial abnormalities will be needed to determine their potential for future progression. Competing Interests: Competing interests: MS reports relationships with Boehringer Ingelheim, Genetech, Peer View, France Foundation, Bioclinica, AbbVie and Lung Life AI outside the scope of this study. EAH reports a relationship with VIDA Diagnostics. CKG reports a relationship with Boehringer Ingelheim outside the scope of this study. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu